Clinical Trial Update: Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of a Melan-A virus-like particle vaccine in patients with advanced malignant melanoma; the update reports saf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Melan-A VLP vaccine (Melan-A virus-like particle vaccine)

Snippet

Sponsor: Cytos Biotechnology AG | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED